At OncoBeta, we're redefining how the world addresses non-melanoma skin cancer (NMSC)—the most common cancer globally—while leveraging our expertise and advanced infrastructure in rhenium-188 and intend to diversify our capabilities and expand our portfolio into new therapeutic areas and markets. As a growing medical device start-up, we're pioneering radionuclide-powered therapies designed to improve patient care and challenge the status quo.
With headquarters in Munich, Germany, and affiliates in Europe, South Africa, and Australia, our mission is global, ambitious, and focused on making a difference for millions of patients worldwide.
APCT1_DE